Heart Failure With Preserved Ejection Fraction in the Elderly Population: Basic Mechanisms and Clinical Considerations

Kimia Gharagozloo; Mozhdeh Mehdizadeh; George Heckman; Robert A. Rose; Jonathan Howlett; Susan E. Howlett; Stanley Nattel

doi:10.1016/j.cjca.2024.04.006

journal article Aug 01, 2024

Heart Failure With Preserved Ejection Fraction in the Elderly Population: Basic Mechanisms and Clinical Considerations

Kimia Gharagozloo Mozhdeh Mehdizadeh George Heckman

Robert A. Rose Jonathan Howlett Susan E. Howlett Stanley Nattel

Canadian Journal of Cardiology Vol. 40 No. 8 pp. 1424-1444 · Elsevier BV

View at Publisher Save 10.1016/j.cjca.2024.04.006

Topics

No keywords indexed for this article. Browse by subject →

References

161

[1]

Dunlay "Epidemiology of heart failure with preserved ejection fraction" Nat Rev Cardiol (2017) 10.1038/nrcardio.2017.65

[2]

Tsujimoto "Abdominal obesity is associated with an increased risk of all-cause mortality in patients with HFpEF" J Am Coll Cardiol (2017) 10.1016/j.jacc.2017.09.1111

[3]

Shah "Phenomapping for novel classification of heart failure with preserved ejection fraction" Circulation (2015) 10.1161/circulationaha.114.010637

[4]

Bursi "Systolic and diastolic heart failure in the community" JAMA (2006) 10.1001/jama.296.18.2209

[5]

Heidenreich "2022 AHA/ACC/HFSA guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines" Circulation (2022)

[6]

Bhatia "Outcome of heart failure with preserved ejection fraction in a population-based study" N Engl J Med (2006) 10.1056/nejmoa051530

[7]

Redfield "Heart failure with preserved ejection fraction: a review" JAMA (2023) 10.1001/jama.2023.2020

[8]

Kobak "Age and sex differences in heart failure with preserved ejection fraction" Front Aging (2022) 10.3389/fragi.2022.811436

[9]

Lakatta "So! What’s aging? Is cardiovascular aging a disease?" J Mol Cell Cardiol (2015) 10.1016/j.yjmcc.2015.04.005

[10]

Fujimoto "Effect of ageing on left ventricular compliance and distensibility in healthy sedentary humans" J Physiol (2012) 10.1113/jphysiol.2011.218271

[11]

Sung "Clinical characteristics and outcomes in the very elderly patients hospitalized for acute heart failure: importance of pharmacologic guideline adherence" Sci Rep (2018) 10.1038/s41598-018-32684-9

[12]

Oktay "The emerging epidemic of heart failure with preserved ejection fraction" Curr Heart Fail Rep (2013) 10.1007/s11897-013-0155-7

[13]

Heart Failure With Preserved Ejection Fraction

Barry A. Borlaug, Kavita Sharma, Sanjiv J. Shah et al.

Journal of the American College of Cardiology 2023 10.1016/j.jacc.2023.01.049

[14]

Kelly "Patient selection in heart failure with preserved ejection fraction clinical trials" J Am Coll Cardiol (2015) 10.1016/j.jacc.2015.03.043

[15]

2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure

Theresa A McDonagh, Marco Metra, Marianna Adamo et al.

European Heart Journal 2021 10.1093/eurheartj/ehab368

[16]

Ducharme "Canadian Cardiovascular Society-Canadian Heart Failure Society focused clinical practice update of patients with differing heart failure phenotypes" Can J Cardiol (2023) 10.1016/j.cjca.2023.04.022

[17]

Verbrugge "Heart failure with preserved ejection fraction in patients with normal natriuretic peptide levels is associated with increased morbidity and mortality" Eur Heart J (2022) 10.1093/eurheartj/ehab911

[18]

Gentile "Epidemiological and clinical boundaries of heart failure with preserved ejection fraction" Eur J Prev Cardiol (2022) 10.1093/eurjpc/zwab077

[19]

Ho "Predicting heart failure with preserved and reduced ejection fraction: the International Collaboration on Heart Failure Subtypes" Circ Heart Fail (2016) 10.1161/circheartfailure.115.003116

[20]

Wong "Heart failure in younger patients: the Meta-analysis Global Group in Chronic Heart Failure (MAGGIC)" Eur Heart J (2014) 10.1093/eurheartj/ehu216

[21]

Wong "Clinical characteristics and outcomes of young and very young adults with heart failure: the CHARM programme (Candesartan in Heart Failure Assessment of Reduction in Mortality and Morbidity)" J Am Coll Cardiol (2013) 10.1016/j.jacc.2013.05.072

[22]

Tromp "Age-related characteristics and outcomes of patients with heart failure with preserved ejection fraction" J Am Coll Cardiol (2019) 10.1016/j.jacc.2019.05.052

[23]

Cleland "Prognosis in heart failure with a normal ejection fraction" N Engl J Med (2007) 10.1056/nejmc076179

[24]

Sun "Sex differences in characteristics and outcomes in elderly heart failure patients with preserved ejection fraction: a post-hoc analysis from TOPCAT" Front Cardiovasc Med (2021) 10.3389/fcvm.2021.721850

[25]

Pandey "Sex and race differences in lifetime risk of heart failure with preserved ejection fraction and heart failure with reduced ejection fraction" Circulation (2018) 10.1161/circulationaha.117.031622

[26]

Chang "Trends in hospitalizations and survival of acute decompensated heart failure in four US communities (2005-2014): ARIC Study Community Surveillance" Circulation (2018) 10.1161/circulationaha.117.027551

[27]

Kristensen "International geographic variation in event rates in trials of heart failure with preserved and reduced ejection fraction" Circulation (2015) 10.1161/circulationaha.114.012284

[28]

Tromp "Global differences in heart failure with preserved ejection fraction: the PARAGON-HF trial" Circ Heart Fail (2021) 10.1161/circheartfailure.120.007901

[29]

Bozkurt Eur J Heart Fail (2021) 10.1002/ejhf.2115

[30]

Borlaug "The pathophysiology of heart failure with preserved ejection fraction" Nat Rev Cardiol (2014) 10.1038/nrcardio.2014.83

[31]

Kao "Characterization of subgroups of heart failure patients with preserved ejection fraction with possible implications for prognosis and treatment response" Eur J Heart Fail (2015) 10.1002/ejhf.327

[32]

Rucker "Defining the phenotypes for heart failure with preserved ejection fraction" Curr Heart Fail Rep (2022) 10.1007/s11897-022-00582-x

[33]

Woolley "Machine learning based on biomarker profiles identifies distinct subgroups of heart failure with preserved ejection fraction" Eur J Heart Fail (2021) 10.1002/ejhf.2144

[34]

Uijl "Identification of distinct phenotypic clusters in heart failure with preserved ejection fraction" Eur J Heart Fail (2021) 10.1002/ejhf.2169

[35]

Cohen "Clinical phenogroups in heart failure with preserved ejection fraction: detailed phenotypes, prognosis, and response to spironolactone" JACC Heart Fail (2020) 10.1016/j.jchf.2019.09.009

[36]

Identification of Frailty in Chronic Heart Failure

Shirley Sze, Pierpaolo Pellicori, Jiawei Zhang et al.

JACC: Heart Failure 2019 10.1016/j.jchf.2018.11.017

[37]

Sanders "The frailty syndrome and outcomes in the TOPCAT trial" Eur J Heart Fail (2018) 10.1002/ejhf.1308

[38]

Howlett "The degree of frailty as a translational measure of health in aging" Nat Aging (2021) 10.1038/s43587-021-00099-3

[39]

Heckman "Frailty, risk, and heart failure care: commission or omission?" J Am Coll Cardiol (2022) 10.1016/j.jacc.2022.07.007

[40]

Warraich "Physical function, frailty, cognition, depression, and quality of life in hospitalized adults ≥ 60 years with acute decompensated heart failure with preserved versus reduced ejection fraction" Circ Heart Fail (2018) 10.1161/circheartfailure.118.005254

[41]

Pandey "Factors associated with and prognostic implications of cardiac troponin elevation in decompensated heart failure with preserved ejection fraction: findings from the American Heart Association Get With The Guidelines-Heart Failure Program" JAMA Cardiol (2017) 10.1001/jamacardio.2016.4726

[42]

Uchmanowicz "Frailty syndrome and self-care ability in elderly patients with heart failure" Clin Interv Aging (2015) 10.2147/cia.s83414

[43]

Uchmanowicz "Frailty and the risk of all-cause mortality and hospitalization in chronic heart failure: a meta-analysis" ESC Heart Fail (2020) 10.1002/ehf2.12827

[44]

Butt "Sacubitril/valsartan and frailty in patients with heart failure and preserved ejection fraction" J Am Coll Cardiol (2022) 10.1016/j.jacc.2022.06.037

[45]

Regan "Protein biomarkers of cardiac remodeling and inflammation associated with HFpEF and incident events" Sci Rep (2022) 10.1038/s41598-022-24226-1

[46]

Hsia "An update on sodium-glucose co-transporter-2 inhibitors for the treatment of diabetes mellitus" Curr Opin Endocrinol Diabetes Obes (2017) 10.1097/med.0000000000000311

[47]

Gager "Effects of SGLT2 inhibitors on ion homeostasis and oxidative stress associated mechanisms in heart failure" Biomed Pharmacother (2021) 10.1016/j.biopha.2021.112169

[48]

Koutentakis "The ketogenic effect of SGLT-2 inhibitors-beneficial or harmful?" J Cardiovasc Dev Dis (2023)

[49]

La Grotta "Repurposing SGLT-2 inhibitors to target aging: available evidence and molecular mechanisms" Int J Mol Sci (2022) 10.3390/ijms232012325

[50]

Anker "Empagliflozin in heart failure with a preserved ejection fraction" N Engl J Med (2021) 10.1056/nejmoa2107038

Showing 50 of 161 references

Metrics

12

Citations

161

References

Details

Published: Aug 01, 2024
Vol/Issue: 40(8)
Pages: 1424-1444
License: View

Authors

University of Calgary, Cumming School of Medicine and Libin Cardiovascular Institute, Alberta, Canada (J.H.).

Funding

Canadian Institutes of Health Research

Heart and Stroke Foundation of Canada

Fonds de Recherche du Québec - Santé

Cite This Article

Kimia Gharagozloo, Mozhdeh Mehdizadeh, George Heckman, et al. (2024). Heart Failure With Preserved Ejection Fraction in the Elderly Population: Basic Mechanisms and Clinical Considerations. Canadian Journal of Cardiology, 40(8), 1424-1444. https://doi.org/10.1016/j.cjca.2024.04.006

Heart Failure With Preserved Ejection Fraction in the Elderly Population: Basic Mechanisms and Clinical Considerations

You May Also Like